- US-listed companies
- Krystal Biotech, Inc.
- Income statement
Krystal Biotech, Inc. (KRYS) Income statement
Market cap
$10.7B
P/E ratio
| 2017/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | - | - | - | 51 | 291 |
| Revenue growth (%) | - | - | - | - | - | - | |
| Research & development | 3 | 16 | 18 | 28 | 42 | 46 | 54 |
| Selling, general & administrative | - | - | - | - | - | - | 114 |
| Operating margin (%) | - | - | - | - | - | ||
| Operating expenses | 5 | 22 | 33 | 68 | 145 | 160 | 225 |
| Operating income | -5 | -22 | -33 | -68 | -145 | -110 | 66 |
| Income before tax | - | - | - | - | - | 13 | 95 |
| Pretax margin (%) | - | - | - | - | - | 25.4 | 32.8 |
| Provision for income taxes | - | - | - | - | - | 2 | 6 |
| Effective tax rate (%) | - | - | - | - | - | ||
| Net income | -8 | -19 | -32 | -70 | -140 | 11 | 89 |
| Net income margin (%) | - | - | - | - | - | ||
| Earnings per share | - | - | - | -3.13 | -5.49 | 0.4 | 3.12 |
| Diluted EPS | - | - | - | -3.13 | -5.49 | 0.39 | 3 |
| EBITDA | - | - | - | - |